Nicolaas H Fourie1, Ralph Michael Peace2, Sarah K Abey1, LeeAnne B Sherwin1, Bridgett Rahim-Williams3, Paul A Smyser1, John W Wiley4, Wendy A Henderson5. 1. Digestive Disorders Unit, National Institute of Nursing Research, National Institutes of Health, DHHS, Bethesda, MD 20892, United States. 2. Digestive Disorders Unit, National Institute of Nursing Research, National Institutes of Health, DHHS, Bethesda, MD 20892, United States; Howard Hughes Medical Institute National Institutes of Health Research Scholar, Chevy Chase, MD 20815, United States. 3. Digestive Disorders Unit, National Institute of Nursing Research, National Institutes of Health, DHHS, Bethesda, MD 20892, United States; National Institute on Minority Health and Health Disparities, National Institutes of Health, DHHS, Bethesda, MD 20892, United States. 4. Internal Medicine, Medical School, University of Michigan, Ann Arbor, MI 48109, United States. 5. Digestive Disorders Unit, National Institute of Nursing Research, National Institutes of Health, DHHS, Bethesda, MD 20892, United States. Electronic address: hendersw@mail.nih.gov.
Abstract
BACKGROUND AND AIMS: MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression and are thus of interest as diagnostic markers, and as clues to etiology and targets of intervention. This pilot study examined whether circulating miRNAs are differentially expressed in patients with IBS. METHODS: miRNA microarrays (NanoString) were run on the whole blood of 43 participants. RESULTS: hsa-miR-150 and hsa-miR-342-3p were found to be significantly elevated (FDR adjusted p≤0.05, ≥1.6 fold change) in IBS patients compared to healthy controls. Neither of these miRNAs showed any relationship to race or sex. hsa-miR-150 is associated with inflammatory bowel disorders and pain, and interacts with a protein kinase (AKT2) through which it may affect inflammatory pathways. hsa-miR-342-3p is predicted to interact with mRNAs involved in pain signaling, colonic motility, and smooth muscle function. CONCLUSIONS: This preliminary study reports the association of two miRNAs, detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers. Published by Elsevier Inc.
BACKGROUND AND AIMS: MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression and are thus of interest as diagnostic markers, and as clues to etiology and targets of intervention. This pilot study examined whether circulating miRNAs are differentially expressed in patients with IBS. METHODS: miRNA microarrays (NanoString) were run on the whole blood of 43 participants. RESULTS:hsa-miR-150 and hsa-miR-342-3p were found to be significantly elevated (FDR adjusted p≤0.05, ≥1.6 fold change) in IBSpatients compared to healthy controls. Neither of these miRNAs showed any relationship to race or sex. hsa-miR-150 is associated with inflammatory bowel disorders and pain, and interacts with a protein kinase (AKT2) through which it may affect inflammatory pathways. hsa-miR-342-3p is predicted to interact with mRNAs involved in pain signaling, colonic motility, and smooth muscle function. CONCLUSIONS: This preliminary study reports the association of two miRNAs, detected in whole blood, with IBS. These miRNAs link to pain and inflammatory pathways both of which are thought to be dysregulated in IBS. Larger sample sizes are needed to confirm their importance and potential as biomarkers. Published by Elsevier Inc.
Authors: Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson Journal: Gastroenterology Date: 2002-06 Impact factor: 22.682
Authors: Angèle P M Kerckhoffs; José J M ter Linde; Louis M A Akkermans; Melvin Samsom Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-02-09 Impact factor: 4.052
Authors: T Piche; G Barbara; P Aubert; S Bruley des Varannes; R Dainese; J L Nano; C Cremon; V Stanghellini; R De Giorgio; J P Galmiche; M Neunlist Journal: Gut Date: 2008-09-29 Impact factor: 23.059
Authors: Johannes Kapeller; Lesley A Houghton; Hubert Mönnikes; Jutta Walstab; Dorothee Möller; Heinz Bönisch; Barbara Burwinkel; Frank Autschbach; Benjamin Funke; Felix Lasitschka; Nikolaus Gassler; Christine Fischer; Peter J Whorwell; Wendy Atkinson; Catherine Fell; Karl J Büchner; Marco Schmidtmann; Ivo van der Voort; Anna-Sophia Wisser; Thomas Berg; Gudrun Rappold; Beate Niesler Journal: Hum Mol Genet Date: 2008-07-09 Impact factor: 6.150
Authors: Wendy A Henderson; Ravi Shankar; Tara J Taylor; Arseima Y Del Valle-Pinero; David E Kleiner; Kevin H Kim; Nader N Youssef Journal: World J Gastrointest Pathophysiol Date: 2012-12-15
Authors: Jennifer Permuth-Wey; Dung-Tsa Chen; William J Fulp; Sean J Yoder; Yonghong Zhang; Christina Georgeades; Kazim Husain; Barbara Ann Centeno; Anthony M Magliocco; Domenico Coppola; Mokenge Malafa Journal: Cancer Prev Res (Phila) Date: 2015-09
Authors: Nicolaas H Fourie; Ralph M Peace; Sarah K Abey; LeeAnne B Sherwin; John W Wiley; Wendy A Henderson Journal: J Vis Exp Date: 2016-11-30 Impact factor: 1.355
Authors: Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller Journal: Nat Rev Dis Primers Date: 2016-03-24 Impact factor: 52.329
Authors: Rehman A Qureshi; Yuzhen Tian; Marguerite K McDonald; Kathryn E Capasso; Sabrina R Douglas; Ruby Gao; Irina A Orlova; James E Barrett; Seena K Ajit; Ahmet Sacan Journal: Mol Neurobiol Date: 2015-06-18 Impact factor: 5.590